Extended hormone therapy doesn't help some prostate cancer - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

Extended hormone therapy doesn't help some prostate cancer patients

Updated:
© iStockphoto.com/ Lilli Day © iStockphoto.com/ Lilli Day

MONDAY, Sept. 23 (HealthDay News) -- For men with intermediate-risk prostate cancer, long-term hormone therapy after radiation therapy provides no survival advantages compared with short-term hormone therapy, according to a new study.

Hormone therapy is used to reduce the levels of male hormones (androgens) such as testosterone, which can stimulate the growth of prostate cancer cells.

Researchers examined data from 133 men with intermediate-risk prostate cancer who underwent either long-term hormone therapy (59 patients) or short-term hormone therapy (74 patients) after receiving external beam radiation therapy.

Ten-year overall survival was 61 percent in the short-term group and 65 percent in the long-term group, which is not a statistically significant difference. Disease-specific survival was 96 percent in both groups.

The study was scheduled for presentation Monday at the annual meeting of the American Society for Radiation Oncology, in Atlanta.

"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS [overall survival] and DSS [disease-specific survival], indicate that this was clearly not the case," study lead author Dr. Amin Mirhadi, a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles, said in a society news release.

"This data supports administering less treatment, which will result in fewer side effects and reduce patients' overall health care costs," Mirhadi added.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Urology Care Foundation has more about hormone therapy for prostate cancer.

Copyright © 2013 HealthDay. All rights reserved.

  • Health WatchMore>>

  • House approves VA health care overhaul

    House approves VA health care overhaul

    Wednesday, July 30 2014 9:12 PM EDT2014-07-31 01:12:40 GMT
    With a new Veterans Affairs secretary in place and an August recess looming, Congress is moving quickly to approve a compromise bill to refurbish the VA and improve veterans' health care.
    The House overwhelmingly approved a landmark bill Wednesday to help veterans avoid long waits for health care that have plagued the Veterans Affairs Department for years.
  • $1,000 Sovaldi now hepatitis treatment of choice

    $1,000 Sovaldi now hepatitis treatment of choice

    Wednesday, July 30 2014 8:58 PM EDT2014-07-31 00:58:45 GMT
    A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
    The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
  • Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.